Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Aim for 2.5-3 liters of water daily during active episodes
Our GLP-3 RETA is produced using advanced peptide synthesis technology and undergoes strict quality control to ensure consistency and purity for laboratory investigations
These expanded clinical uses drastically widen the addressable patient population
Stevanato estimates that oral GLP-1s will capture a 30% market share by 2030, though precise forecasting remains elusive
There is also a trial specifically testing whether retatrutide prevents heart attacks and strokes (TRIUMPH-3, 1,800 people), and a head-to-head trial comparing retatrutide directly against tirzepatide (the active ingredient in Zepbound) under identical conditions (NCT06662383, 800 patients)
There is also the very real possibility there will be continual churn among GLP-1 users, as people cycle on and off the drugs throughout their lifetime
